Fatma Gül Yurdakul

Dr. Fatma Gül Yurdakul


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2019 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
HBHatice Bodur
Hatice Bodur
FYFatma Gül Yurdakul
Fatma Gül Yurdakul
HÇHasan Fatih Çay
Hasan Fatih Çay
ÜUÜlkü Uçar
Ülkü Uçar
YKYaşar Keskin
Yaşar Keskin
ISİlhan Sezer
İlhan Sezer

1 January 2015 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
FYFatma Gül Yurdakul
Fatma Gül Yurdakul
HBHatice Bodur
Hatice Bodur
ÖÇÖzgür Öztop Çakmak
Özgür Öztop Çakmak
CAcan ateş
can ateş
FSFiliz Sivas
Filiz Sivas
ÖTÖzlem Yılmaz Taşdelen
Özlem Yılmaz Taşdelen
Gül Yurdakul F, et al. J Clin Neurol. 2015 Jul;11(3):234-240. http://dx.doi.org/10.3988/jcn.2015.11.3.234

13 November 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
PSPınar Kaya Subaşı
Pınar Kaya Subaşı
TGTuba Güler
Tuba Güler
FYFatma Gül Yurdakul
Fatma Gül Yurdakul
ŞAŞebnem Ataman
Şebnem Ataman
HBHatice Bodur
Hatice Bodur


21 December 2020 in Turkish Journal of Physical Medicine and Rehabilitation
Verified
Journal Article
Open access
RURezan Koçak Ulucaköy
Rezan Koçak Ulucaköy
FYFatma Gül Yurdakul
Fatma Gül Yurdakul
HBHatice Bodur
Hatice Bodur
This study aims to evaluate the efficacy of extracorporeal shock wave therapy (ESWT) in carpal tunnel syndrome (CTS) compared to the wrist splint treatment. Between April 2016 and March 2017, a total of 189 patients (22 males, 167 females, mean age 48.8±9.5 years, range, 24 to 70 years) with mild-to-moderate CTS were included in this double-blind, prospective, randomized, placebo-controlled study. The patients were divided into four treatment groups using stratified randomization: splint group (Group 1, n=47), splint+ESWT (Group 2, n=47), ESWT (Group 3, n=45), and splint+placebo ESWT (Group 4, n=50). All patients were evaluated at baseline, and one and three months. Pain using the Visual Analog Scale (VAS), finger pinch strength, Boston Carpal Tunnel Questionnaire (BCTQ), Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), and electrophysiological examination were assessed. A total of 168 patients completed the study. There was no significant difference among the four groups in terms of age, sex, comorbid diseases, symptom duration, VAS-pain, BCTQ, and LANSS scores (p>0.05). Pain and functionality significantly improved in all groups (p<0.05). In the group with ESWT and using wrist splint combined, a greater improvement of the hand function and electrophysiological measures was observed. Our study results show that ESWT is a valuable and reliable treatment modality for mild-to-moderate CTS.

30 June 2021 in Archives of Rheumatology
Verified
Journal Article
Open access
ŞAŞebnem Ataman
Şebnem Ataman
ISİlHan Sezer
İlHan Sezer
BSBanu Sarifakioğlu
Banu Sarifakioğlu
KNKemal Nas
Kemal Nas
MNMehmet Nayi̇mOğlu
Mehmet Nayi̇mOğlu
FYFatma Gül Yurdakul
Fatma Gül Yurdakul
Objectives: This study aims to evaluate the effectivity of Familial Mediterranean Fever Quality of Life (FMF-QoL) Scale for the measurement of QoL in patients with FMF and to perform correlations between related clinical variables in Turkish patients. Patients and methods: This multicenter prospective study performed between December 2017 and November 2018 included 974 FMF patients (334 males, 640 females; median age: 35; range, 26 to 45 years). Sociodemographic characteristics and clinical features were recorded. All participants were asked to complete the FMF-QoL Scale, Short Form-36 (SF-36), Hospital Anxiety and Depression Scale (HADS), Health Assessment Questionnaire (HAQ), and Functional Assessment of Chronic Illness Therapy (FACIT) Scale. Results: The median FMF-QoL Scale score was 26. Higher FMF-QoL Scale scores were shown to be related to female sex, illiteracy or primary education, monthly low-income (US$20 years), a higher number of attacks per month (>1/month), and severe disease. FMF-QoL Scale scores were correlated negatively with subscales of SF-36, and positively with HADS-anxiety and HADS-depression scores, HAQ and FACIT. Conclusion: Female sex, smoking, lower educational status, more severe disease, fatigue, and functional impairment were associated with poor QoL. FMF-QoL Scale was noted as a valid and simple patient-reported outcome instrument and correlated with the SF-36 scale.